Profusa announced a Letter of Intent to acquire PanOmics, a multi-omics diagnostics platform from BioInsights LLC, for $30.0 million. The deal is positioned as a strategic expansion into molecular diagnostics by the commercial-stage digital health company.
Profusa announced a Letter of Intent to acquire PanOmics, a multi-omics diagnostics platform from BioInsights LLC, for $30.0 million. The deal is positioned as a strategic expansion into molecular diagnostics by the commercial-stage digital health company.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
mildly positive
Sentiment Score
0.35
Ticker Sentiment
